Ankylosing spondylitis (AS) led to bone formation that resulted in the rare complete fusion of ankle and foot bones in a 69-year-old man, a case study reported. His AS was discovered only after hospitalization for kidney problems and an examination for gout. The researchers suggested the terminology “boot sign”…
High levels of the pro-inflammatory molecule GM-CSF were found in the bloodstream of people with active ankylosing spondylitis (AS) and strongly correlated with disease activity, a pilot study suggested. Despite helping to lower disease activity, anti-TNF therapies did not affect GM-SCF levels. As such, GM-SCF may represent a…
A new algorithm based on artificial intelligence (AI) could help clinicians reach an earlier diagnosis of akylosing spondylitis (AS), a study found. Using only demographic and clinical data derived from standard blood tests, the method does not require more costly and less widely available imaging techniques, researchers say. The algorithm…
People with ankylosing spondylitis (AS)-related kyphosis — a “humpback” appearance — showed good post-surgery outcomes with a technique called satellite rods, a Chinese study shows. The use of satellite rods had been linked to a lower rate of complications in people undergoing spinal surgery, but its use in AS-related kyphosis…
The U.S. Food and Drug Administration (FDA) has approved a new, more highly concentrated formulation of Hadlima (adalimumab-bwwd), a biosimilar to AbbVie’s Humira (adalimumab), for the treatment of ankylosing spondylitis. As a biosimilar, Hadlima has similar properties, safety, and efficacy to an approved biological treatment, in this…
A new and citrate-free formulation of Taltz (ixekizumab) is being made available to treat adults with active ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA) patients who have signs of inflammation. Symptoms of nr-axSpA are similar to AS, but without X-ray evidence of inflammation. This formulation of the Eli Lilly therapy was…
The first healthy volunteer in the U.S. has been dosed in a Phase 1 clinical trial evaluating IMG-004, an oral inhibitor of Bruton’s tyrosine kinase (BTK) being developed as a potential therapy for a wide range of inflammatory and autoimmune diseases, including ankylosing spondylitis (AS). In the Phase 1…
Health Canada has approved Rinvoq (upadacitinib) to treat active ankylosing spondylitis (AS) in adults who fail to respond to a biologic disease-modifying anti-rheumatic drug (DMARD) or cannot tolerate these therapies. Rinvoq, developed and marketed by AbbVie, can be used alone or in combination with non-steroidal anti-inflammatory drugs (NSAIDs), a common first…
Medications that block the activity of the pro-inflammatory molecule interleukin-17A (IL-17A) can ease symptoms of ankylosing spondylitis (AS), but further research is needed to evaluate their safety, according to an analysis. These findings were in the study “Efficacy and safety of interleukin-17A inhibitors in patients with ankylosing…
People with rare disorders have a worse healthcare experience than those affected by chronic diseases, according to the results of an international survey conducted by Eurordis-Rare Diseases Europe. Indeed, rare disease patients overall give their healthcare experience a medium-low rating, of 2.5 on a scale of 1 to 5,…
Get regular updates to your inbox.